GHK-Cu
The most-studied copper peptide in skincare — a naturally occurring tripeptide (GHK, Gly-His-Lys) whose active tissue form is the copper complex GHK-Cu, with extensive evidence for skin remodeling, collagen synthesis, wound healing, and anti-aging.
What is GHK-Cu?
GHK is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine — originally isolated by Loren Pickart in 1973 while investigating why young plasma restored youthful protein synthesis in older liver tissue. GHK has an unusually strong affinity for copper(II) ions, and in vivo it is believed to exist predominantly bound to copper as the complex GHK-Cu, which is the biologically active form responsible for most of the tissue-remodeling, wound-healing, and gene-expression effects described in the literature. 'GHK' and 'GHK-Cu' are often used interchangeably in informal usage, but in precise terms GHK is the bare tripeptide and GHK-Cu is the copper-chelated complex; cosmetic and compounded formulations almost always supply the latter, whether labeled as 'GHK,' 'copper peptide,' 'copper tripeptide-1,' or 'GHK-Cu.' Plasma GHK levels decline roughly two-fold between the twenties and sixties — reported as approximately 200 ng/mL in young adults dropping to ~80 ng/mL by age 60 — which provides the biological rationale for replenishment-focused anti-aging interest in the peptide.
What GHK-Cu Is Investigated For
GHK-Cu is one of the better-evidenced peptides in cosmetic and dermatologic applications, with decades of research supporting its effects on skin rejuvenation, wound healing, and collagen production. Topical and injectable forms both have human clinical data, though topical use is more extensively studied and widely available as a regulated cosmetic ingredient. Endogenous GHK-Cu levels decline ~60% between ages 20 and 60, which is a compelling biological rationale for replenishment. Hair growth and broader cellular anti-aging claims are based on in vitro gene-expression data and smaller clinical observations — real but less definitive than the skin evidence. Overall, GHK-Cu is an unusually well-characterized peptide for a compound in the wellness space.
History & Discovery
GHK was isolated in 1973 by Loren Pickart at the University of Washington, who was investigating why human plasma from younger donors appeared to induce older liver tissue to synthesize proteins at a more youthful rate. The active factor turned out to be a small tripeptide — glycyl-L-histidyl-L-lysine — that bound copper with unusual affinity. Pickart's subsequent work over the following decades established that plasma GHK levels drop substantially with age (roughly two-fold from the twenties to the sixties), and that the copper complex GHK-Cu is the biologically relevant form in tissue remodeling. Through the 1980s and 1990s, the compound moved from plasma curiosity to clinical dermatology via the company ProCyte, which commercialized Cu-peptide-containing wound-care and cosmetic products. The cosmetic channel has been the peptide's most durable path to market — topical GHK-Cu has been sold as a dermatologic active in creams and serums for more than thirty years. Injectable and compounded systemic GHK-Cu is a much newer and more loosely regulated category that grew out of the broader peptide-therapy movement in the 2010s, with human data lagging far behind the extensive topical and preclinical literature.
How It Works
GHK-Cu acts as a signal that tells your body to repair and remodel tissue. It stimulates collagen production, attracts immune cells to wound sites, and has antioxidant properties. As we age, our natural GHK-Cu levels drop, which may contribute to slower healing and skin aging.
GHK-Cu modulates the expression of a large number of human genes — studies suggest it affects over 4,000 genes. It upregulates collagen synthesis (types I and III), decorin, and other extracellular matrix components. It stimulates metalloproteinases for tissue remodeling, attracts macrophages and mast cells for wound repair, promotes angiogenesis, and has demonstrated anti-inflammatory and antioxidant effects. It also activates the ubiquitin-proteasome system for removal of damaged proteins.
Evidence Snapshot
Human Clinical Evidence
Moderate. Multiple human studies on wound healing and skin rejuvenation. Widely used in dermatological applications.
Animal / Preclinical
Strong. Extensive animal data on wound healing, tissue remodeling, and gene expression modulation.
Mechanistic Rationale
Very strong. One of the best-characterized peptides in terms of gene expression effects.
Research Gaps & Open Questions
What the current literature has not yet settled about GHK-Cu:
- 01Human in vivo quantification of topical skin penetration — while in vitro skin permeation is characterized, the fraction of an applied dose reaching viable epidermis and dermis in real-world human use is not precisely established across formulation types.
- 02Controlled injectable human trials — systemic GHK-Cu has essentially no published Phase II or III human data; claims about systemic dosing, pharmacokinetics, and clinical endpoints rest on extrapolation from topical and animal work.
- 03Hair-growth evidence — mechanistic rationale around follicular stem cells is interesting, but controlled human trials on scalp application for androgenetic alopecia are limited and effect sizes are modest compared to established treatments.
- 04Long-term safety of chronic topical use beyond observational cosmetic-product data — while the track record is reassuring, rigorous long-term randomized safety data is not available.
- 05Head-to-head comparisons with other established cosmetic actives (retinoids, growth factors, vitamin C) at typical consumer use levels — most GHK-Cu trials are vs. placebo rather than vs. active comparators.
- 06Formulation-to-formulation variability — 'contains GHK-Cu' is not a uniform claim; actual peptide content, copper-loading ratio, and delivery vehicle vary widely between commercial products.
Forms & Administration
GHK-Cu is available topically (creams, serums) and as an injectable (subcutaneous). Topical forms are widely available over the counter. Injectable protocols should be determined by a qualified clinician.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
For topical cosmetic formulations, GHK-Cu is typically included at 1–3% in serums and creams, with higher-end professional products occasionally reaching 5%. Because the copper complex has a characteristic blue color, concentrations above ~2% produce visibly tinted product. Injectable and compounded subcutaneous protocols discussed in the peptide-therapy space commonly use 1–2 mg per dose, but these protocols are not backed by controlled human dose-ranging trials.
Frequency
Topical: once or twice daily, applied to clean skin before heavier occlusive moisturizers. Most published clinical protocols used twice-daily application for 8–12 weeks before measuring endpoints. Injectable protocols (where used) are typically once daily or every other day — but again, this cadence is based on clinician practice patterns rather than trial data.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Topical use is generally continuous and indefinite — GHK-Cu is treated as a maintenance cosmetic active, not a cycled therapy. For injectable protocols, 4–8 week courses are most commonly described, often with a washout before restarting, though the rationale for cycling is empirical rather than mechanism-driven.
Protocol Notes
Skin-penetration considerations dominate topical formulation. GHK-Cu is small (~340 Da) and penetrates the stratum corneum better than most peptide actives, but depth of dermal delivery is still limited and vehicle-dependent. Formulations using liposomal encapsulation, penetration enhancers, or microneedle delivery are an active area of research precisely because passive diffusion through intact skin delivers only a modest fraction to viable epidermis and papillary dermis. Copper-peptide products should not be co-applied with strong acids (high-concentration vitamin C, glycolic acid) in the same layer — the low pH can destabilize the copper complex — though sequential use at different times of day is fine. Injectable GHK-Cu is a much less standardized category. Reconstitution and sourcing concerns mirror the broader compounded-peptide landscape: product purity and actual peptide content are not always verified, and systemic copper delivery introduces considerations (serum copper, ceruloplasmin status) that topical use does not.
Topical GHK-Cu is regulated as a cosmetic ingredient, not a drug. Injectable and compounded GHK-Cu are not FDA-approved for any medical indication. The topical literature does not transfer automatically to systemic use.
Timeline of Effects
Onset
For topical application, acute hydration and surface-texture effects may be noticeable within days, but collagen- and matrix-mediated changes (fine line softening, firmness) typically require 4–8 weeks of consistent use. Wound-healing acceleration in clinical trials (e.g., post-laser resurfacing) has been measured as faster re-epithelialization in the first 7–14 days.
Peak Effect
Published topical trials typically show maximum measured benefit at 8–12 weeks of twice-daily application, which is the window in which collagen turnover would plausibly manifest visibly. Continued use is assumed to maintain the effect rather than produce additional gains beyond that window.
After Discontinuation
Topical benefits recede as skin turnover replaces the treated tissue; most clinical protocols describe a gradual return toward baseline over weeks to a few months after stopping use. There is no described withdrawal or rebound pattern. For injectable protocols, the lack of human pharmacokinetic data means any claims about post-cessation persistence are speculative.
Common Questions
Who GHK-Cu Is NOT For
- •Wilson's disease and other disorders of copper metabolism — even the modest copper delivered by cosmetic products is a theoretical concern, and systemic GHK-Cu is generally contraindicated.
- •Known hypersensitivity to copper or to GHK-Cu formulations; contact dermatitis to copper is uncommon but reported.
- •Active malignancy — because GHK-Cu stimulates angiogenesis and broadly resets gene expression patterns, clinicians typically avoid systemic use in patients with active cancer pending better safety data; topical use on non-lesional skin is considered lower risk.
- •Pregnancy and breastfeeding — no adequate safety data exists for systemic use; topical cosmetic use on intact skin is generally considered low-risk but has not been rigorously studied in pregnancy.
- •Open, actively infected wounds — GHK-Cu wound-healing studies generally used it on clean wound beds; use on infected wounds is not well studied.
- •Pediatric systemic use — no data; topical cosmetic use is not relevant to pediatric populations.
Drug & Supplement Interactions
Clinically documented drug interactions for GHK-Cu are minimal for topical use and poorly characterized for systemic use. Topical GHK-Cu is chemically incompatible with co-applied low-pH actives — high-concentration L-ascorbic acid (vitamin C), glycolic acid, and other strong acids can destabilize the copper-peptide complex when layered simultaneously, so these are typically separated to different times of day rather than combined in one routine. Retinoids, niacinamide, and most peptide actives are compatible with concurrent or alternating use. For systemic injectable use (where practiced), theoretical interactions parallel those of other angiogenic agents: anti-angiogenic oncology therapies (bevacizumab, VEGF-targeted tyrosine kinase inhibitors) would be expected to oppose GHK-Cu's mechanism, and co-administration should be avoided. Copper-chelating drugs (penicillamine, trientine) used for Wilson's disease and copper-dependent metabolic considerations (ceftriaxone copper interactions in neonates, etc.) are relevant contexts for systemic rather than topical use. Patients on any regular medication using compounded injectable GHK-Cu should disclose it to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Topical forms are generally very well tolerated
- • Injectable forms should be used under clinician guidance
- • Those with Wilson's disease or copper metabolism disorders should avoid
What We Don't Know
Systemic effects of injectable GHK-Cu at various doses are not fully characterized in large clinical trials.
Legal Status
United States
Topical GHK-Cu is regulated as a cosmetic ingredient and is broadly available without prescription in creams, serums, and wound-care products. It is not FDA-approved as a drug for any indication. Injectable GHK-Cu does not have FDA drug approval; compounded injectable preparations have historically been available through state-licensed compounding pharmacies, but the FDA's 2023 review of peptides eligible for 503A compounding has narrowed that pathway for several peptides, and copper-peptide's status in that framework continues to evolve. Research-chemical suppliers selling GHK-Cu powder are not authorized channels for human use.
International
Topical GHK-Cu is broadly permitted as a cosmetic ingredient in the EU, UK, Canada, Australia, Japan, and most major markets. Injectable or systemic use is not approved by EMA, MHRA, TGA, or Health Canada as a licensed medicine; regulatory posture toward compounded or research-chemical supply varies by jurisdiction.
Sports & Competition
GHK-Cu is not explicitly named on the WADA Prohibited List. Topical cosmetic use raises no realistic doping concern. Systemic injectable use would fall into the ambiguous zone under WADA's S0 category, which prohibits substances not approved by any governmental regulatory authority for human therapeutic use — athletes under WADA code should assume systemic GHK-Cu is prohibited out of caution.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
GHK-Cu affects over 4,000 genes, so it can reverse almost any age-related condition.
Reality
The 4,000-gene figure comes from a Connectivity Map analysis showing broad transcriptional modulation in cultured cells. That is mechanistically interesting but does not translate into clinical effect sizes in humans. In vivo, topical GHK-Cu is a competent cosmetic active with modest measured benefit for photoaging and wound healing — not a systemic age-reversal therapy.
Myth
Topical GHK-Cu penetrates deeply enough to rebuild the dermis like an injected treatment.
Reality
GHK-Cu is smaller and more permeable than many peptide actives, but passive diffusion through intact stratum corneum still delivers only a limited fraction to the papillary dermis, and essentially none to the reticular dermis. Serums work primarily at the epidermis and upper dermis. Treatments that genuinely remodel deep dermis (professional resurfacing, microneedling, injectable biostimulators) work on a different scale.
Myth
Injectable GHK-Cu is FDA-approved and has the same safety profile as the cosmetic cream.
Reality
Injectable GHK-Cu is not FDA-approved for any indication. Systemic exposure carries different considerations than surface application — copper dosing, angiogenic signaling, and sourcing quality are all meaningful variables that topical use does not raise.
Myth
All copper peptide products are basically the same.
Reality
Actual peptide concentration, copper-loading ratio, pH, formulation pH stability, and vehicle (simple serum vs. liposomal vs. encapsulated) vary dramatically across products that all claim 'copper peptide.' The research literature showing benefit used specific, stable formulations — not every product on shelves is comparable.
Myth
Using GHK-Cu with vitamin C doubles the anti-aging effect.
Reality
High-concentration L-ascorbic acid is acidic enough to destabilize the copper-peptide complex when applied in the same layer. Combining the two is not additive — it can reduce the activity of both. Sensible routines separate them (AM vs. PM, or alternate days), which is a different practice than 'stacking' them simultaneously.
Published Research
34 studiesTherapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych V, Shypilova I, and Bolgova O, Frontiers in Aging 2026. Review covering nine peptides (including GHK-Cu) in the aging-and-healthspan context, summarizing the age-related plasma decline data and gene-modulation breadth that anchor GHK-Cu's anti-aging positioning.
Site-Specific Detection of Copper-Peptide Coordination in Solution Phase by Two-Dimensional Infrared Spectroscopy
An injectable hydroxyapatite microsphere filler loaded with GHK-Cu tripeptide for anti-Inflammatory and antioxidant
Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms
Dimeric copper peptide incorporated hydrogel for promoting diabetic wound healing
Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.
Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?
Palmitoyl copper peptide and acetyl tyrosine complex enhances melanin production in both A375 and B16 cell lines
Novel Applications of CE-ICP-MS/MS: Monitoring of Antiaging GHK-Cu Cosmetic Component Encapsulation in Liposomes
Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application
Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex-vivo skin tests
De Novo Design of a Self-Assembled Artificial Copper Peptide that Activates and Reduces Peroxide
Biomimetic Hydrogel Scaffolds with Copper Peptide-Functionalized RADA16 Nanofiber Improve Wound Healing in Diabetes
Polyaspartic acid, 2-acrylamido-2-Methyl propane sulfonic acid and sodium alginate based biocompatible stimuli responsive polymer gel for controlled release of GHK-Cu peptide for wound healing
The potential of GHK as an anti-aging peptide.
Enhanced biological properties of collagen/chitosan-coated poly(ε-caprolactone) scaffold by surface modification with GHK-Cu peptide and 58S bioglass
In Vitro and in Vivo Studies of pH-Sensitive GHK-Cu-Incorporated Polyaspartic and Polyacrylic Acid Superabsorbent Polymer
Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways
Electrophoretic deposition of GHK-Cu loaded MSN-chitosan coatings with pH-responsive release of copper and its bioactivity
Investigations of the Copper Peptide Hepcidin-25 by LC-MS/MS and NMR
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.
Pivotal review analyzing Broad Institute Connectivity Map data showing GHK-Cu modulates the expression of 4,000+ human genes, resetting many disease-associated gene patterns toward a healthier state across tissue repair, anti-cancer, and anti-inflammatory pathways.
GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis
The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice
An Artificial Neural Network Based Analysis of Factors Controlling Particle Size in a Virgin Coconut Oil-Based Nanoemulsion System Containing Copper Peptide
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.
Comprehensive review of GHK-Cu's role in skin regeneration, detailing its stimulation of collagen, decorin, and glycosaminoglycan synthesis alongside activation of metalloproteinases for ECM remodeling — establishing GHK-Cu as one of the best-characterized peptides in dermatology.
Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction
Microneedle-Mediated Delivery of Copper Peptide Through Skin
Copper-peptide complex structure and reactivity when found in conserved His-X(aa)-His sequences
The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health
Landmark review presenting evidence that GHK-Cu may counteract oxidative stress and age-related cognitive decline, including potential relevance to Alzheimer's disease through suppression of genes linked to neurodegeneration.
Impact of single-dose application of TGF-β, copper peptide, stanozolol and ascorbic acid in hydrogel on midline laparatomy wound healing in a diabetic mouse model
Speciation of copper-peptide complexes in water solution using DFTB and DFT approaches: case of the [Cu(HGGG)(Py)] complex
Transition metals as electron traps. I. Structures, energetics, electron capture, and electron-transfer-induced dissociations of ternary copper-peptide complexes in the gas phase
On-line electrogeneration of copper-peptide complexes in microspray mass spectrometry
Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
RCT in 100 patients demonstrating that topical GHK-Cu significantly accelerated wound healing after CO2 laser resurfacing, with faster re-epithelialization and reduced erythema compared to placebo — one of the strongest human clinical trials for GHK-Cu.
Popular Stacks Including GHK-Cu
GLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu)
GLOW is a popular pre-mixed compounded peptide blend combining BPC-157 tissue repair, TB-500 cell migration, and GHK-Cu collagen remodeling in a single 70 mg vial. Also covers the two-peptide BPC-157 + GHK-Cu pairing for practitioners sourcing vials separately.
KLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu + KPV)
KLOW is a pre-mixed four-peptide compounded blend combining BPC-157 and TB-500 systemic repair, GHK-Cu collagen remodeling, and KPV anti-inflammatory coverage in a single 80 mg vial. It extends the popular GLOW formulation with an explicit anti-inflammatory layer.
Quick Facts
- Class
- Copper Peptide
- Tier
- B
- Evidence
- Moderate
- Safety
- Well-Studied
- Updated
- May 2026
- Citations
- 34PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.